Literature DB >> 22613999

Liver and skin histopathology in adults with acid sphingomyelinase deficiency (Niemann-Pick disease type B).

Beth L Thurberg1, Melissa P Wasserstein, Thomas Schiano, Fanny O'Brien, Susan Richards, Gerald F Cox, Margaret M McGovern.   

Abstract

Acid sphingomyelinase deficiency (ASMD) is a lysosomal storage disorder characterized by the pathologic accumulation of sphingomyelin (SM) in multiple cell types, and occurs most prominently within the liver, spleen, and lungs, leading to significant clinical disease. Seventeen ASMD patients underwent a liver biopsy during baseline screening for a phase 1 trial of recombinant human acid sphingomyelinase (rhASM) in adults with Niemann-Pick disease type B. Eleven of the 17 were enrolled in the trial and each received a single dose of rhASM and underwent a repeat liver biopsy on day 14. Biopsies were evaluated for fibrosis, SM accumulation, and macrophage infiltration by light and electron microscopy. When present, fibrosis was periportal and pericellular, predominantly surrounding affected Kupffer cells. Two baseline biopsies exhibited frank cirrhosis. SM was localized to isolated Kupffer cells in mildly affected biopsies and was present in both Kupffer cells and hepatocytes in more severely affected cases. Morphometric quantification of SM storage in liver biopsies ranged from 4% to 44% of the microscopic field. Skin biopsies were also performed at baseline and day 14 to compare the SM distribution in a peripheral tissue with that of liver. SM storage was present at lower levels in multiple cell types of the skin, including dermal fibroblasts, macrophages, vascular endothelial cells, vascular smooth muscle cells, and Schwann cells. This phase 1 trial of rhASM in adults with ASMD provided a unique opportunity for a prospective assessment of hepatic and skin pathology in this rare disease and their potential usage as pharmacodynamic biomarkers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613999      PMCID: PMC3396757          DOI: 10.1097/PAS.0b013e31825793ff

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  18 in total

1.  The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations.

Authors:  Calogera M Simonaro; Robert J Desnick; Margaret M McGovern; Melissa P Wasserstein; Edward H Schuchman
Journal:  Am J Hum Genet       Date:  2002-10-04       Impact factor: 11.025

2.  High-resolution light microscopy (HRLM) and digital analysis of Pompe disease pathology.

Authors:  Colleen M Lynch; Jennifer Johnson; Charles Vaccaro; Beth L Thurberg
Journal:  J Histochem Cytochem       Date:  2005-01       Impact factor: 2.479

3.  Niemann-Pick disease type B: first-trimester prenatal diagnosis on chorionic villi and biochemical study of a foetus at 12 weeks of development.

Authors:  M T Vanier; J Boue; Y Dumez
Journal:  Clin Genet       Date:  1985-10       Impact factor: 4.438

4.  Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

Authors:  Beth L Thurberg; Helmut Rennke; Robert B Colvin; Steven Dikman; Ronald E Gordon; A Bernard Collins; Robert J Desnick; Michael O'Callaghan
Journal:  Kidney Int       Date:  2002-12       Impact factor: 10.612

5.  Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.

Authors:  Beth L Thurberg; Colleen Lynch Maloney; Charles Vaccaro; Kendra Afonso; Anne Chun-Hui Tsai; Edward Bossen; Priya S Kishnani; Michael O'Callaghan
Journal:  Lab Invest       Date:  2006-10-30       Impact factor: 5.662

6.  Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies.

Authors:  Beth L Thurberg; H Randolph Byers; Scott R Granter; Robert G Phelps; Ronald E Gordon; Michael O'Callaghan
Journal:  J Invest Dermatol       Date:  2004-04       Impact factor: 8.551

7.  Niemann-Pick disease: sixteen-year follow-up of allogeneic bone marrow transplantation in a type B variant.

Authors:  S Victor; J B S Coulter; G T N Besley; I Ellis; R J Desnick; E H Schuchman; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

8.  Lipid abnormalities in children with types A and B Niemann Pick disease.

Authors:  Margaret M McGovern; Tilla Pohl-Worgall; Richard J Deckelbaum; William Simpson; David Mendelson; Robert J Desnick; Edward H Schuchman; Melissa P Wasserstein
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

9.  Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.

Authors:  Beth L Thurberg; John T Fallon; Richard Mitchell; Thomas Aretz; Ronald E Gordon; Michael W O'Callaghan
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

10.  The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study.

Authors:  Melissa P Wasserstein; Robert J Desnick; Edward H Schuchman; Sabera Hossain; Sylvan Wallenstein; Carin Lamm; Margaret M McGovern
Journal:  Pediatrics       Date:  2004-11-15       Impact factor: 7.124

View more
  17 in total

1.  Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency.

Authors:  Melissa P Wasserstein; Simon A Jones; Handrean Soran; George A Diaz; Natalie Lippa; Beth L Thurberg; Kerry Culm-Merdek; Elias Shamiyeh; Haig Inguilizian; Gerald F Cox; Ana Cristina Puga
Journal:  Mol Genet Metab       Date:  2015-05-30       Impact factor: 4.797

2.  Multimodal imaging including optical coherence tomography angiography in patients with type B Niemann-Pick disease.

Authors:  Selim Bolukbasi; Cezmi Dogan; Ertugrul Kiykim; Akin Cakir; Burak Erden; Alper Halil Bayat; Mustafa Nuri Elcioglu; Ayse Cigdem Aktuglu Zeybek
Journal:  Int Ophthalmol       Date:  2019-04-11       Impact factor: 2.031

3.  Cirrhosis and liver failure: expanding phenotype of Acid sphingomyelinase-deficient niemann-pick disease in adulthood.

Authors:  Olivier Lidove; Frédéric Sedel; Frédéric Charlotte; Roseline Froissart; Marie T Vanier
Journal:  JIMD Rep       Date:  2014-04-10

Review 4.  Foam Cells: One Size Doesn't Fit All.

Authors:  Valentina Guerrini; Maria Laura Gennaro
Journal:  Trends Immunol       Date:  2019-11-12       Impact factor: 16.687

Review 5.  Types A and B Niemann-Pick disease.

Authors:  Edward H Schuchman; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2016-12-16       Impact factor: 4.797

6.  Enhanced Delivery and Effects of Acid Sphingomyelinase by ICAM-1-Targeted Nanocarriers in Type B Niemann-Pick Disease Mice.

Authors:  Carmen Garnacho; Rajwinder Dhami; Melani Solomon; Edward H Schuchman; Silvia Muro
Journal:  Mol Ther       Date:  2017-06-09       Impact factor: 11.454

7.  Control of autophagy maturation by acid sphingomyelinase in mouse coronary arterial smooth muscle cells: protective role in atherosclerosis.

Authors:  Xiang Li; Ming Xu; Ashley L Pitzer; Min Xia; Krishna M Boini; Pin-Lan Li; Yang Zhang
Journal:  J Mol Med (Berl)       Date:  2014-01-25       Impact factor: 4.599

8.  Genetics of Lipid-Storage Management in Caenorhabditis elegans Embryos.

Authors:  Verena Schmökel; Nadin Memar; Anne Wiekenberg; Martin Trotzmüller; Ralf Schnabel; Frank Döring
Journal:  Genetics       Date:  2016-01-15       Impact factor: 4.562

Review 9.  Niemann-Pick disease treatment: a systematic review of clinical trials.

Authors:  Alejandro Santos-Lozano; Diana Villamandos García; Fabian Sanchis-Gomar; Carmen Fiuza-Luces; Helios Pareja-Galeano; Nuria Garatachea; Gisela Nogales Gadea; Alejandro Lucia
Journal:  Ann Transl Med       Date:  2015-12

10.  Novel first-dose adverse drug reactions during a phase I trial of olipudase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency).

Authors:  Margaret M McGovern; Melissa P Wasserstein; Brian Kirmse; W Lane Duvall; Thomas Schiano; Beth L Thurberg; Susan Richards; Gerald F Cox
Journal:  Genet Med       Date:  2015-04-02       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.